Clinical cancer research : an official journal of the American Association for Cancer Research
International Standard Serial Number (ISSN)
publication venue for
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.
A novel HSP90 inhibitor-drug conjugate to SN38 is highly effective in small cell lung cancer (SCLC).
Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens.
A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients.
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.
A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC.
Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer.
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Inhibition of established micrometastases by targeted drug delivery via cell surface-associated GRP78.
Validation of a radiosensitivity molecular signature in breast cancer.
Expression and functional significance of HtrA1 loss in endometrial cancer.
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma.
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression.
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells.
The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas.